Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Perf tech 3 > TEG > Flashcards

TEG Flashcards

(71 cards)

Start Studying
1
Q

Hemostasis: tightly regulated process by

A
  • Activation

* Clot formation • Clot lysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Clot: platelet-fibrin network

A

• Platelets form plug • Clotting factors reinforce platelets • Fibrin acts as a glue • Clot strength

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

platelets percentage of platelet- fibrin network

A

80%-90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

fibrin percentage of platelet fibrin network

A

10%-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Component Measurements • PT/INR:

A

measures extrinsic clotting (VIIa, Xa, IIa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Component Measurements PTT:

A

measures intrinsic clotting (XIIa, Xia, IXa, IIa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

other two component measurement tests

A

• Fibrinogen concentration • Platelet Count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Measurement of component interactions • TEG

A

Shows net effect “whole picture” of hemostasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is TEG

A

A whole blood hemostasis analyzer • Point of care test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how does TEG machine work

A

Cup oscillates • Pin is attached to torsion
wire • Clot binds pin to cup • Degree and magnitude
of pin motion are functions of the clot kinetics and mechanical properties
• System generates a hemostasis profile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

coagulation parameters of TEG graph

A

enzymatic(R) Fibrinogen (K, alpha)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

enzymatic(R) what it measures

A

clotting time, coag. factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fibrinogen (K, alpha) what it measures

A

clot kinetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

fibrinolysis parameters of TEG graph

A

thrombolysins (Ly30, EPL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

thrombolysins (Ly30, EPL) what it measure

A

clot stability and clot breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

thrombolysins (Ly30, EPL) what it measure

A

clot stability and clot breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

formal definition of TEG parameters (R)

A

latency from time blood was placed in TEG until initial fibrin formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

formal definition of TEG parameters (ALPHA)

A

rapidity (kinetics) of fibrin building and cross linking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

formal definition of TEG parameters (K)

A

measure of rapidity to reach a certain clot strength

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

formal definition of TEG parameters (MA)

A

Max amplitude is a direct function of the max dynamic properties of fibrin and platelet bonding via GPIIB/IIIA and represents ultimate strength of fibrin clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

formal definition of TEG parameters (Cl)

A

coagulation index is a linear combo of above parameters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

formal definition of TEG parameters (LY30)

A

measures the rate of amplitude reduction 30 minutes after MA. Gives indication of stability of clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

formal definition of TEG parameters (LY30)

A

measures the rate of amplitude reduction 30 minutes after MA. Gives indication of stability of clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

or more simply (R)

A 
Reaction time (time to clot formation). Likely variable is 
Coagulation Factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
or more simply (α)
Speed of fibrin accumulation. likely variable is | Fibrinogen
26
or more simply (K)
Time elapsed until clot reaches a fixed strength | likely variable isFibrinogen
27
or more simply (MA)
Highest vertical amplitude of TEG tracing | likely variable isPlatelets
28
or more simply (LY30)
% of amplitude reduction 30 minutes after its maximum | likely variable is Fibrinolysis
29
TEG assays Standard (kaolin)
uses parameters listed above
30
TEG assays Rapid TEG
Uses tissue factor in place of kaolin to speed up the reaction R-value is replaced by TEG-ACT value Other parameters the same
31
TEG assays heparinase
Used on bypass or post bypass alongside a standard TEG
32
TEG assays platelet mapping
Determines to what degree platelet function is inhibited due to pharmacological inhibition of either the arachidonic acid (AA) or adenosine diphosphate (ADP) pathways
33
AA: Aspirin • ADP: Clopidogrel
Run alongside a standard TEG and a TEG with added AA or ADP. • Calculates platelet inhibition as a percentage
34
elongated ( R) thrombin formation abnormalities Possible cause of imbalance:
Slow enzymatic | reaction
35
elongated ( R) thrombin formation abnormalities Possible Etiologies
Factor deficiency/dysfunction • FFP • Protamine
36
elongated ( R) thrombin formation abnormalities | Common Treatments:
• FFP • Protamine
37
LOW (α) angle fibrinogen abnormalities. Possible cause of imbalance
• Slow rate of fibrin formation
38
LOW (α) angle fibrinogen abnormalities. Possible etiologies.
``` • Low fibrinogen levels or function • Insufficient rate/amount of thrombin generation • Platelet deficiency/dysfunction ```
39
LOW (α) angle fibrinogen abnormalities | Common Treatments
FFP • Cryoprecipitate
40
LOW (α) angle fibrinogen abnormalities. Possible etiologies.
``` • Low fibrinogen levels or function • Insufficient rate/amount of thrombin generation • Platelet deficiency/dysfunction ```
41
LOW (α) angle fibrinogen abnormalities | Common Treatments
FFP • Cryoprecipitate
42
Low MA platelet function abnormalities. Possible causes: •
Insufficient platelet-clot | formation
43
Low MA platelet function abnormalities, Possible etiologies
Poor platelet function • Low platelet count • Low fibrinogen levels or function
44
Low MA platelet function abnormalities. Common treatments:
• Platelets
45
High MA platelet function abnormalities. possible causes:
Excessive platelet activity
46
High MA platelet function abnormalities. Possible etiologies
• Platelet hypercoagulability
47
High MA platelet function abnormalities. Common Treatments
Antiplatelet agents
48
R between 7-10 min
slight decrease in clotting factors. give x 1FFP or 4 ml/kg
49
R between 11-14 min
moderate decrease in clotting factors. give x 2FFP or 8 ml/kg
50
R between >14 min
significant decrease in clotting factors. give x 4FFP or 16 ml/kg
51
MA between 49-54 mm
slight decrease in platelet function. .3 mcg/kg DDAVP
52
MA between 41-48 mm
moderate decrease in platelet function. x5 platelet units
53
MA
significant decrease in platelet function. x 10 platelet units
54
(α) angle less than 45 degress
moderate decrease in fibrinogen levels. .06 u/kg cryoprecipitate
55
(α) angle less than 45 degress
moderate decrease in fibrinogen levels. .06 u/kg cryoprecipitate
56
LY30 AT 7.5% or greater with C.I. less than 3
primary fibrinolysis. antifibrinolytic of choice
57
LY30 AT 7.5% or greater with C.I. greater than 3
secondary fibrinolysis. anticoagulant of choice
58
LY30 LESS THAN 7.5% or greater with C.I. greater than 3
prothrombotic state. anticoagulant of choice
59
platelet mapping measures
Measures the effect of antiplatelet agents on platelet function • Measures the patient’s maximum platelet function as a reference point • Measures the percentage of inhibition relative to the patient’s reference point
60
platelet mapping antiplatelet drugs, ADP receptor inhibitors
Examples: clopidogrel, ticlopidine
61
platelet mapping antiplatelet drugs, Arachidonic acid pathway inhibitors
• Example: aspirin
62
platelet mapping antiplatelet drugs, GPIIb/IIIa inhibitors
Examples: abciximab, tirofiban, eptifibatide
63
why platelet mapping
* Individual response to antiplatelet drugs determines clinical outcome * Knowing percent of platelet inhibition is insufficient to determine therapeutic efficacy * Knowledge of maximum platelet function is also required as a reference point
64
why platelet mapping
* Individual response to antiplatelet drugs determines clinical outcome * Knowing percent of platelet inhibition is insufficient to determine therapeutic efficacy * Knowledge of maximum platelet function is also required as a reference point
65
rotational elastometry ROTEM
• Stationary cup, rotating spindle • Clot impedes rotation of the pin • Additional tests available
66
INTEM
contains phospholipid and ellagic acid as activators amd provides info. similar to that of the APTT
67
EXTEM
contains tissue factor as an activator and provides info. similar to that of the PT
68
HEPTEM
contains lyophilised heparinase for neutralizing heparin
69
APTEM
contains aprotinin for inhibiting fibrinolysis
70
FIBTEM
utilises cytochalasin D, a platelet inhibitor which blocks platelet contribution to clot formation. this allows qualitative analysis of the functional fibrinogen component
71
ECATEM
contains ecarin so it is similar to ecarin clotting time. this makes it sensitive to presence of direct thrombin inhiitors

Perf tech 3 (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions